Progress in the treatment of advanced gastric cancer

Abstract

Gastric cancer is one of the most common malignant tumors in the digestive system. Surgery is currently considered to be the only radical treatment. As surgical techniques improve and progress is made in traditional radiotherapy, chemotherapy, and the implementation of neoadjuvant therapy, the 5-year survival rate of early gastric cancer can reach >95%. However, the low rate of early diagnosis means that most patients have advanced-stage disease at diagnosis and so the best surgical window is missed. Therefore, the main treatment for advanced gastric cancer is the combination of neoadjuvant chemoradiotherapy, molecular-targeted therapy, and immunotherapy. In this article, we summarize several common methods used to treat advanced gastric cancer and discuss the progress made in the treatment of gastric cancer in detail. Only clinical practice and clinical research will allow us to prolong the survival time of patients and allow the patients to truly benefit by paying attention to the individual patient characteristics, drug choice, and developing a reasonable and comprehensive treatment plan.

Circular RNA circHIAT1 inhibits proliferation and epithelial‐mesenchymal transition of gastric cancer cell lines through downregulation of miR‐21

“…As a result, more than 70% of the patients develop into advanced GC and even lose the opportunity for surgical resection. [ 5 ] Thus, there is an urgent need to find an effective method to monitor and treat GC.…”

Downregulated microRNA‐150 upregulates IRX1 to depress proliferation, migration, and invasion, but boost apoptosis of gastric cancer cells

“…Surgery is currently regarded as the only radical treatment of gastric cancer. However, the difficulty in early diagnosis resulting from lack of specific signs tends to lead to a miss in the best opportunity of surgery in patients with gastric cancer . Naturally, we had the idea to find a way out of this tough situation.…”

ATPR‐induced G0/G1 phase arrest in gastric cancer cells by regulating the binding of 14‐3‐3ε and filamin A

“…For gastric cancer, early diagnosis and surgical resection are currently considered the preferred treatment, and the 5‐year survival rate is more than 95%. However, due to the low rate of early diagnosis, most patients have advanced‐stage disease at diagnosis, and the main treatment is the combination of chemotherapy, molecular‐targeted therapy, and immunotherapy . Molecular‐targeted therapy provides an antitumor effect by regulating some key proteins in the cell cycle, cell growth, and apoptosis signaling pathways.…”